Dimensional Fund Advisors LP Has $68,000 Holdings in SOPHiA GENETICS SA (NASDAQ:SOPH)

Dimensional Fund Advisors LP lifted its holdings in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) by 23.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 21,619 shares of the company’s stock after acquiring an additional 4,115 shares during the quarter. Dimensional Fund Advisors LP’s holdings in SOPHiA GENETICS were worth $68,000 at the end of the most recent quarter.

Separately, Federated Hermes Inc. lifted its holdings in SOPHiA GENETICS by 40.5% in the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after buying an additional 28,819 shares during the period. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

SOPH stock opened at $2.96 on Monday. The firm has a market cap of $197.39 million, a price-to-earnings ratio of -2.72 and a beta of 1.03. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $6.28. The company’s fifty day simple moving average is $3.04 and its 200 day simple moving average is $3.33.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $17.78 million during the quarter, compared to analyst estimates of $16.76 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. On average, analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, BTIG Research set a $5.00 target price on shares of SOPHiA GENETICS in a report on Thursday, March 6th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.